Author's response to reviews

Title: Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers

Authors:

Anne Letessier (letessiera@marseille.fnclcc.fr)
Fabrice Sircoulomb (sircoulombf@marseille.fnclcc.fr)
Christophe Ginestier (ginestti@med.umich.edu)
Nathalie Cervera (cerveran@marseille.fnclcc.fr)
Florence Monville (monvillef@marseille.fnclcc.fr)
Veronique Gelsi-boyer (gelsiv@marseille.fnclcc.fr)
Benjamin Esterni (esternib@marseille.fnclcc.fr)
Christophe Zemmour (zemmourn@marseille.fnclcc.fr)
Pascal Finetti (finettip@marseille.fnclcc.fr)
Patrice Viens (viensp@marseille.fnclcc.fr)
Emmanuelle Charaf-jauffret (jauffrete@marseille.fnclcc.fr)
Jocelyne Jacquemier (jacquemierj@marseille.fnclcc.fr)
Daniel Birnbaum (birnbaum@marseille.inserm.fr)
Max Chaffanet (chaffanetm@marseille.fnclcc.fr)

Version: 3 Date: 11 October 2006

Author's response to reviews:

Dear Editor,

Thank you very much for the review process of our manuscript MS ndegrees 5383020001115572 from Letessier et al., entitled "Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers"

We have answered the comments as follows:

To the Editor :
1- The sections : (i) Headings, (ii) Methods, (iii) Figures and (iv) Additional files were corrected or modified and any highlighting/tracking were removed from the text as suggested by the Editor.

In Method section/Patients and histological samples, additional information was added to document the details of the institutional review board that granted ethical approval for the study. Modifications suggested by the reviewer 1 needed to add a new table (Table 2). Consequently, a table shuffling has been created between the former tables 1 and 2 generating now a total of five tables

To the Reviewer one (Peter Schraml)
The amplification frequencies of RAB11FIP1 and FGFR1 (8p12) as well as MYBL2, ZNF217 and AURKA (20q13) are now listed in a new table (see below) (Table 2) as suggested. They were only briefly discussed because previously reported [5;29], separately.

Region of amplification Gene regions Number of FISH informative cases % of tumors with amplification
8p12 RAB11FIP1 279 13,30%
FGFR1 319 9,40%
20q13 MYBL2 265 5,7%
ZNF217 233 9,9%
AURKA 282 3,5%

We hope that the reviewer will be satisfied by the corrections. Thank you again for giving us the opportunity to improve our manuscript.

Sincerely,

Max Chaffanet